← All trials
NCT06475274
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2024
- Primary completion
- Aug 1, 2025
- Completion date
- Oct 30, 2025
- First posted
- Jun 26, 2024
- Last posted
- Nov 4, 2024
- Enrollment
- 161
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guard Therapeutics ABLead sponsor
- Guard Therapeutics ABOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.